Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Canadian Intellectual Property Office Application No. 3,000,369 has been granted.
"Millions of conventional ECGs are performed worldwide every week and AI-ECG technology is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, while reducing treatment costs. We are pleased to receive this latest patent grant in Canada. Over recent years we have conscientiously built an extensive international intellectual property portfolio across major markets which we expect will provide competitive advantage and intrinsic corporate value," said Andrew Simpson, CEO of HeartSciences.
The United States Patent and Trademark Office has issued eight utility patents and one design patent to HeartSciences. In addition, HeartSciences has 14 international design registrations and 19 international utility patents granted in jurisdictions including China, Japan, South Korea, the United Kingdom, France, Germany, Mexico, the United Arab Emirates, Brazil, and Australia.
Investor contact
Mark Komonoski, Integrous Communications · 877-255-8483 · [email protected]